Cannabix Technologies Files Patent for Proprietary Laboratory Drug Analysis Device
03 Januar 2024 - 3:30PM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2024/1/3/sgmrkcannabix.webp)
VANCOUVER, British Columbia, Canada -- January 3, 2024 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (the "Company or Cannabix") developer of marijuana
and alcohol breath testing devices reports that it has filed a
provisional patent application titled, "Sample Delivery Systems and
Methods for Low Volatility Analytes Obtained from Breath". This
provisional patent application covers new innovations and
intellectual property related to the detection of low and
semi-volatile substances (like delta-9 THC) using its proprietary
Mass Spectrometer Breath Sampler ("MSBS") technology. The MSBS is
an innovative hardware device which allows for direct desorption of
human breath samples into a mass spectrometer without the need for
any pre-preparation (see Figure 1). The MSBS substantially
simplifies laboratory analysis methods, reduces sample turnaround
times (within a few minutes), and provides a truly novel method for
drug screening using breath.
Highlights and Updates:
-
The Company has filed a new provisional patent for its MSBS
related technology allowing for the rapid analysis of human breath
for difficult to detect, non-volatile compounds in breath (like
delta-9 THC).
-
Cannabix's MSBS technology along with the Breath Collection Unit
("BCU") (see Figure 2) have been providing consistent results in
the detection of delta-9 THC in breath from smoking and THC infused
edibles consumption.
-
Cannabix has been using the MSBS to quantify delta-9 THC in
human breath samples. Currently, a limit of detection and limit of
quantification have been achieved with human subjects in the low
picogram range. This allows detection of THC from smoking and
edibles up to 4 hours after consumption.
-
Cannabix is advancing discussions with industry leading forensic
laboratory organizations on how to best integrate its novel MSBS
hardware into current forensic testing and analysis methods.
-
Effective January 1, 2024, new legislative measures, California
Assembly Bill 2188 (AB 2188), Senate Bill 700 (SB 700), and
Washington State Senate Bill 5123 (SB 5123), now restrict employers
from taking adverse actions against job applicants based on their
off-duty use of cannabis or on the results of pre-employment drug
tests that find non-psychoactive cannabis metabolites (1).
Cannabix's marijuana breathalyzer system (using the BCU and MSBS)
has been specifically built to detect recent cannabis
use – detecting Delta-9 THC, the active, psychoactive
compound in cannabis – using breath samples, within 1-4 hours after
consumption.
![](https://investorshub.advfn.com/uimage/uploads/2024/1/3/wojkeScreen_Shot_2024-01-03_at_8.16.37_AM.png)
The new provisional patent covers various novel aspects for
efficient analysis of low volatility analytes from human breath
developed by the Company. The patent includes the unique internal
geometry of the sampler that has been optimized to maximize the
delivery of the analyte. Combined with liquid secondary adsorption
(LSA), the concept behind the sample capture and release, the MSBS
has repeatedly demonstrated efficient detection of delta-9 THC.
This is a unique capability in that current methods focus mostly on
volatile analytes in breath, while the non-volatile components can
provide much more additional information about the subject – not
only marijuana use but also for example health related biomarkers.
Cannabix has been continuously improving collection efficiency of
the BCU, and sample transfer efficiency of the MSBS such that the
results are comparable or better relative to conventional liquid
chromatography-mass spectrometry (LC-MS) forensic methods, which
are often time-consuming and expensive.
MSBS Technology and BCU
The Company's mass spectrometer coupled laboratory "MS Breath
Sampler" (Figure 1) and handheld Breath Collection Unit ("BCU",
Figure 2) are being used together to provide a new method for drug
detection that complements gold-standard mass spectrometry with
sample collection taking about 2 minutes and the complete sample
analysis from start to finish taking less than 5 minutes. This
equipment significantly simplifies laboratory analysis methods,
reduces sample turnaround times (thus minimizing operating costs),
while maintaining sensitive, precise results.
MSBS compared to legacy LCMS methods
The MSBS is a novel method for efficient collection of analytes
of low volatility from human breath utilizing LSA technique. The
LSA concept has successfully demonstrated efficient capturing and
releasing of THC using the breath aerosol as a carrier of viscous
liquid particle analytes as well as a secondary adsorbent to
prevent sample loss from surface contact deposition. Legacy
conventional quantifying methods rely on the use of complex
time-consuming liquid chromatography-mass spectrometry (LC-MS)
research-based methods which require multiple preparation steps
(e.g., solvent extraction and preconcentration) that are plagued
with sample loss. This type of analysis is complex and can take
hours to perform. Using the Cannabix equipment the results of a
breath sample can be processed within a fraction of the time
without any sample preparation, preconcentration, or derivatisation
steps resulting in an efficient and simple workflow.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and
alcohol breathalyzer technologies for law enforcement, workplaces
and laboratories. Cannabix is working to develop delta-9 THC and
alcohol screening devices. Delta-9 THC is the psychoactive
component of marijuana that causes impairment. Breath testing for
delta-9 THC would allow employers and law enforcement
to identify recent marijuana use that better aligns with
impairment. Cannabix is the developer of contactless
breath alcohol detection devices for employers and other
settings.
We seek Safe Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that its development of
breathalyzer technologies will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. The is no
assurance that the Company will enter into any partnerships to
advance any of its corporate initiatives or technologies. There is
no assurance that any "patent pending" or "provisional patents"
technologies licensed by the Company or owned by the Company will
receive patent status by regulatory authorities. The Company is not
currently selling commercial breathalyzers. Actual results and
future events could differ materially from those anticipated in
such information. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend to update these forward-looking
statements.
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
Von Jul 2024 bis Aug 2024
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
Von Aug 2023 bis Aug 2024